Outpatient Oncology Infusion Market Analysis and Forecast to 2032: By Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors), Application (Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer), Therapy (Chemotherapy, Targeted

Outpatient Oncology Infusion Market Analysis and Forecast to 2032: By Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors), Application (Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer), Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy), Mode (Intramuscular (IM), Intravenous (IV), Subcutaneous), and Region

The global Outpatient Oncology Infusion Market was valued at USD 62.5 billion in 2022, and it is anticipated to grow to USD 205.3 billion by 2032, at a CAGR of 12.4% during the forecast period.

The outpatient oncology infusion centers offer a variety of treatments, such as chemotherapy, blood transfusions, platelet transfusions, IV antibiotics, and hydration and electrolyte replacement. It also provides long-term and short-infusion therapy to patients in an appropriate manner.

Global Outpatient Oncology Infusion Market Scope and Report Structure

Market Trends and Drivers

The market is acquiring significant importance due to increasing technological advancements in infusion pumps. Additionally, the growing demand for outpatient infusion therapy for cancer treatment is anticipated to boost market expansion. The rise in advanced technology has allowed infusion pumps to exhibit electronic health records integration, such as built-in infusion and drug library of the list of drugs stored in the smart pump’s memory. Such advancement helps to prevent medication errors. Further, this advancement has enabled infusion systems to connect to the electronic medical record by interoperability software. This provides the ability to communicate and share data accurately, effectively, and securely with different devices.

Market Restraints and Challenges

The key restraints and challenges in the Outpatient Oncology Infusion market include the stringent regulations, the need for a large amount of capital, high cost of treatment, and the lack of awareness among individuals regarding advanced treatment.

Global Outpatient Oncology Infusion Market Segmental Overview

The report analyses the global Outpatient Oncology Infusion Market based on Product, Therapy, Mode, Application and Region.

Global Outpatient Oncology Infusion Market by Product

Based on the product, the Outpatient Oncology Infusion market is divided into Infusion Pumps, Intravenous Sets, IV Cannulas, and Needleless Connectors. Intravenous sets segment is set to register a significant CAGR through 2032. Intravenous sets are flexible tubes that help with smooth medication. These sets are mostly used to deliver photosensitive fluids to oncology patients and protect them from light during distribution. Also, it delivers light-sensitive APIs and pharmaceutical products. Such benefits associated with this product will accelerate industry trends.

Global Outpatient Oncology Infusion Market by Application

By application, the industry is bifurcated into Lung Cancer, Liver Cancer, Breast Cancer, and Prostate Cancer. Prostate cancer segment exceeded USD xx billion in 2022. This is due to growing awareness among individuals regarding the prostate cancer therapy along with rising prevalence of prostate cancer. Moreover, increasing adoption of innovative infusion pump in cancer diagnosis coupled with development of targeted and immunotherapies therapies for the treatment of prostate cancer is projected to drive the business landscape.

Global Outpatient Oncology Infusion Market by Therapy

Based on therapy, the industry is categorized into Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy. Outpatient oncology infusion market from targeted therapy segment is projected to record a lucrative CAGR in the coming years. Targeted therapies are utilized to specifically target cancer cells while causing no harm to the body's normal cells. It is frequently combined with additional treatments like regular or traditional chemotherapy, radiation therapy, or staging operations. The targeted treatments aid in the treatment of cancer including multiple myeloma, prostate cancer, melanoma, lymphoma, and breast cancer. This is done by interfering with specific protein types that aid tumor development and circulation. The rate of cancer development in the body can be considerably lowered using this method.

Global Outpatient Oncology Infusion Market by Mode

Based on mode, the Outpatient Oncology Infusion market is divided into Intramuscular (IM), Intravenous (IV), and Subcutaneous. The intramuscular (IM) segment is projected to witness substantial CAGR from 2023 to 2032. The intramuscular method is used to administer the majority of vaccinations. Such a method of administration lowers adverse effects at the injection site. Intramuscular injections are useful because they deliver drugs deep into muscle tissue, resulting in rapid absorption into the bloodstream.

Geographical Analysis of Global Outpatient Oncology Infusion Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the Outpatient Oncology Infusion Market growth, recording the highest CAGR during the forecast period. According to the Global Entrepreneurship Monitor, U.S. start-ups make up more than 17.4% of the country's total population. Thus, it represents an excellent opportunity for cloud lending in the region. Moreover, this region's collaboration between banks and market lenders is rapidly increasing. These factors are expected to drive the growth of the Outpatient Oncology Infusion Market during the projected period in this region.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The growth of the regional market can be attributed to the growing awareness in countries such as China, India, and Japan, about the benefits offered by alternative lending platforms. The aggressive efforts being pursued by various organizations across the Asia Pacific to promote the utilization of alternative lending platforms are also expected to contribute to the growth of the regional market. For instance, in June 2022, a Singapore-based startup named Helicap raised USD 6.94 million in funding, and it has developed a technology for crunching data points of loans which can help in evaluating the creditworthiness of over 500 lenders across South East Asia and Oceania.

Major Players in the Global Outpatient Oncology Infusion Market

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Outpatient Oncology Infusion market include B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc., IRadimed Corporation, Nipro Corporation, Terumo Corporation, Smiths Medical, Medtronic PLC, Roche Diagnostics, and Teleflex, Inc., among others.

COVID-19 Impact

Throughout the projected period, the COVID-19 pandemic is anticipated to have a significant impact on the growth of the industry. The alternative lending platforms witnessed a substantial increase in users as many people suffered financial losses owing to the outbreak. The COVID-19 impact on the market is observed to be moderate. During initial days of COVID-19 pandemic, treatment pathways were altered including outpatient care to minimize the exposer of cancer patient to COVID-19 infection.

Recent Developments

• In December 2021, B. Braun Medical launched the next generation OnGuard 2 CSTD. This device prevents the release of chemotherapy drug vapors and aerosols under extreme conditions. Such a product launch helped the company to enhance its product portfolio and its market position.
• In May 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
• In September 2018, Pfizer received U.S. FDA approval for VIZIMPRO as the first line treatment for patients with EGFR-mutate metastatic non-small cell lung cancer.

Please Note:This report will be delivered by publisher within 3-4 business days of order confirmation.